Alpha Cognition Inc. logo

Alpha Cognition Inc. (ACOG)

Market Closed
15 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
5. 99
0
0%
$
93.03M Market Cap
- P/E Ratio
- Div Yield
23,213 Volume
- Eps
$ 5.99
Previous Close
Analysts:
Add Transaction
Day Range
5.85 6.18
Year Range
4.5 11.54
Want to track ACOG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Alpha Cognition Inc. (NASDAQ:ACOG ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Lauren D'Angelo - Chief Operating Officer Michael E. McFadden - CEO & Director Conference Call Participants David Joseph Storms - Stonegate Capital Partners, Inc., Research Division Raghuram Selvaraju - H.C.

Seekingalpha | 10 months ago
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock

What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock

Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 11 months ago
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?

Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?

Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks | 0 year ago
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.

Seekingalpha | 1 year ago
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.

Zacks | 1 year ago
Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. (NASDAQ:ACOG ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Henry Du - Interim Chief Financial Officer Michael McFadden - Chief Executive Officer Lauren D'Angelo - Chief Operating Officer Conference Call Participants Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings, and welcome to the Alpha Cognition Earnings Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago